Search
Diabetes Paid Clinical Trials in Wisconsin
A listing of 25 Diabetes clinical trials in Wisconsin actively recruiting volunteers for paid trials and research studies in various therapeutic areas.
1 - 12 of 25
The state of Wisconsin currently has 25 active clinical trials seeking participants for Diabetes research studies. These trials are conducted in various cities, including Milwaukee, Madison, Green Bay and Marshfield.
Featured Trial
Heart Failure Clinical Trial
Recruiting
You or someone you love may be eligible for a heart failure clinical study. Eligible participants will receive study-related assessments, care, and treatment at no cost. You may be reimbursed for travel while participating. See if you are eligible.
Conditions:
Heart Failure
Congestive Heart Failure
Chronic Heart Failure
Heart Failure
Congestive
Featured Trial
Type 2 Diabetes (T2DM) Trials
Recruiting
Type 2 Diabetes (T2DM) trials near you are looking for participants to help push medical research forward. Click through to learn more!
Conditions:
Type 2 Diabetes (T2DM)
Featured Trial
Cardiovascular Disease Trials
Recruiting
Cardiovascular Disease trials near you are looking for participants to help push medical research forward. Click through to learn more!
Conditions:
Cardiovascular Disease
Featured Trial
Chronic Kidney Disease and High Blood Pressure
Recruiting
Conditions:
Kidney Disease
Chronic Kidney Disease
* Compensation for time may be available
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Featured Trial
Healthy Volunteer Trials
Recruiting
Healthy trials near you are looking for participants to help push medical research forward. Click through to learn more!
Conditions:
Healthy
A Safety, Tolerability, and Efficacy Study of VX-264 in Participants With Type 1 Diabetes
Recruiting
The purpose of the study is to evaluate the safety, tolerability, and efficacy of VX-264 in participants with type 1 diabetes (T1D).
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
06/17/2024
Locations: University of Wisconsin, Madison, Wisconsin
Conditions: Type 1 Diabetes
A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk
Recruiting
The main purpose of this study is to determine safety and efficacy of orforglipron compared with insulin glargine in participants with type 2 diabetes and obesity or overweight at increased cardiovascular risk. The study will last approximately 2 years may include up to 27 visits.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/17/2024
Locations: St. Vincent Hospital d/b/a Prevea Health, Green Bay, Wisconsin +1 locations
Conditions: Type 2 Diabetes, Obesity, Overweight or Obesity, Overweight, Cardiovascular Diseases, Chronic Kidney Disease
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor
Recruiting
This study will look at how well CagriSema helps people with type 2 diabetes lower their blood sugar and body weight. CagriSema is a new investigational medicine. Doctors may not yet prescribe CagriSema. CagriSema will be compared to a medicine called tirzepatide that doctors may prescribe in some countries. Participants will get either CagriSema or tirzepatide. Which treatment participant get is decided by chance like flipping a coin. Participant will have an equal chance of receiving either dr... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/14/2024
Locations: Prevea Health, Green Bay, Wisconsin
Conditions: Type 2 Diabetes
Enhancing Diabetes Management Approaches for Black and Hispanic Patients With Uncontrolled Diabetes
Recruiting
The purpose of the study is to learn about the best way to enhance pharmacy-related care for diabetes self-management.
This research is being done because we want to improve use of medicines and diabetes management among Black and Hispanic adults with type 2 diabetes and find out which of type of support may improve diabetes self-management for Black and Hispanic adults.
Participants will be assigned to one of 4 groups, and will either:
receive care as usual; or,
receive added medicine manage... Read More
Gender:
All
Ages:
Between 18 years and 90 years
Trial Updated:
06/10/2024
Locations: University of Wisconsin, Madison, Wisconsin
Conditions: Diabetes, Diabetes Type 2
A Study of REACT in Subjects With Type 2 Diabetes Mellitus and Chronic Kidney Disease
Recruiting
The purpose of this study is to assess the safety and efficacy (including durability) of up to 2 REACT injections given 3 months (+30 days) apart and delivered percutaneously into biopsied and non-biopsied contralateral kidneys in participants with T2DM and CKD.
Gender:
All
Ages:
Between 30 years and 80 years
Trial Updated:
06/10/2024
Locations: University of Wisconsin-Madison, Madison, Wisconsin
Conditions: Type 2 Diabetes Mellitus, Chronic Kidney Diseases
A Research Study to See if Kidney Damage in People With Chronic Kidney Disease and Type 2 Diabetes Living With Overweight or Obesity Can be Reduced by CagriSema Compared to Semaglutide, Cagrilintide and Placebo
Recruiting
This study will look if CagriSema can lower kidney damage in people with chronic kidney disease (CKD), type 2 diabetes (T2D) and overweight or obesity. CagriSema is a new investigational medicine. CagriSema cannot yet be prescribed by doctors. The study will compare CagriSema to the 2 medicines semaglutide and cagrilintide, when they are taken alone. It will also compare CagriSema to a "dummy" medicine (also called placebo) without any active ingredient. Participant will either get CagriSema 2.4... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/10/2024
Locations: Clinical Inv Spec, Inc.Kenosha, Kenosha, Wisconsin
Conditions: Chronic Kidney Disease, Type 2 Diabetes, Obesity
SPYRAL AFFIRM Global Study of RDN With the Symplicity Spyral RDN System in Subjects With Uncontrolled HTN
Recruiting
The purpose of this single-arm interventional study is to evaluate the long-term safety, efficacy, and durability of the Symplicity Spyral system in subjects treated with renal denervation.
Additionally, long-term follow-up data will also be collected from eligible subjects previously treated in the SPYRAL PIVOTAL-SPYRAL HTN-OFF MED and SPYRAL HTN-ON MED studies.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/07/2024
Locations: Advocate Aurora Health-Aurora St. Luke's Medical Center (ASLMC), Milwaukee, Wisconsin
Conditions: Hypertension, Vascular Diseases, Cardiovascular Diseases, Chronic Kidney Diseases, Diabetes Mellitus
A Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor
Recruiting
The study will look at how well CagriSema helps people lower their blood sugar and body weight. CagriSema is a new weekly medicine that combines two medicines called semaglutide and cagrilintide. CagriSema will be compared to the two medicines semaglutide and cagrilintide, when they are taken alone. CagriSema will also be compared to a "dummy" medicine without any active ingredient. The study will be done in participants who have type 2 diabetes. Participants will take the study medicine togethe... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/06/2024
Locations: St. Vincent Hosp-Prevea Health, Green Bay, Wisconsin
Conditions: Type 2 Diabetes Mellitus
A Safety, Tolerability, and Efficacy Study of VX-880 in Participants With Type 1 Diabetes
Recruiting
This study will evaluate the safety, tolerability and efficacy of VX-880 infusion in participants with Type 1 diabetes mellitus (T1D) and impaired awareness of hypoglycemia (IAH) and severe hypoglycemia.
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
06/05/2024
Locations: University of Wisconsin, Madison, Wisconsin
Conditions: Diabetes Mellitus, Type 1, Impaired Hypoglycemic Awareness, Severe Hypoglycemia
Role of Autophagy in Type 2 Diabetes Microvascular Dysfunction
Recruiting
The goal of this clinical trial is to examine the role of autophagy on microvascular function in adults with Type 2 Diabetes. The main question it aims to answer are:
Does presence of Type 2 Diabetes reduce autophagy and impair microvascular function?
Does exposure to high glucose impair autophagy and subsequently microvascular function?
Participants will undergo 2 study days. The primary outcome will be in vivo microvascular function testing. Following the first study day participants will un... Read More
Gender:
All
Ages:
Between 18 years and 80 years
Trial Updated:
05/30/2024
Locations: Medical College of Wisconsin, Milwaukee, Wisconsin
Conditions: Type 2 Diabetes, Healthy Aging
TArgeting Type 1 Diabetes Using POLyamines (TADPOL)
Recruiting
The goal of this clinical trial is to test a drug known as DFMO in people with Type 1 Diabetes (T1D). The main question[s] it aims to answer are:
Does it reduce stress on the cells that make insulin?
Does it preserve what is left of the body's insulin production? Participants will take either DFMO or a placebo (looks like DFMO but has no active ingredients) two times a day for about 6 months. Participants will have 6 in person visits and 1 phone visit over a period of 12 months. Visits will inc... Read More
Gender:
All
Ages:
Between 4 years and 40 years
Trial Updated:
05/30/2024
Locations: Medical College of Wisconsin, Milwaukee, Wisconsin
Conditions: Type 1 Diabetes
PREvention of CardIovascular and DiabEtic kidNey Disease in Type 2 Diabetes
Recruiting
PRECIDENTD is a randomized, open label, pragmatic clinical trial designed to compare rates of the total number of cardiovascular, kidney, and death events among two alternative treatments for patients with type 2 diabetes (T2D) and either established atherosclerotic cardiovascular disease (ASCVD) or at high risk for ASCVD. To accomplish this objective, we will randomly assign 6,000 patients with established T2D and ASCVD or high-risk for ASCVD in a 1:1 allocation to sodium-glucose cotransporter-... Read More
Gender:
All
Ages:
Between 40 years and 80 years
Trial Updated:
05/20/2024
Locations: Medical College of Wisconsin, Milwaukee, Wisconsin
Conditions: Type2Diabetes, ASCVD
1 - 12 of 25